US Stock MarketDetailed Quotes

FDMT 4D Molecular Therapeutics

Watchlist
  • 3.630
  • +0.070+1.97%
Close Mar 28 16:00 ET
  • 3.630
  • 0.0000.00%
Post 20:01 ET
168.08MMarket Cap-1.22P/E (TTM)

4D Molecular Therapeutics Key Stats

4D Molecular Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 442.500K--
--2025/Q1-- / 446.330K--
--2024/Q41.000K / 2.284M--
--2024/Q33.000K / 601.140K--
--2024/Q25.000K / 685.710K--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 442.500K--
--2025/Q1-- / 446.330K--
--2024/Q41.000K / 2.284M--
--2024/Q33.000K / 601.140K--
--2024/Q25.000K / 685.710K--

Unlock Free Earnings Estimates

4D Molecular Therapeutics Earnings Reports

Read more

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More